Phase II study of oral S-1 plus irinotecan in patients with advanced colorectal cancer: Hokkaido Gastrointestinal Cancer Study Group HGCSG0302

Jpn J Clin Oncol. 2005 Feb;35(2):88-9. doi: 10.1093/jjco/hyi025.

Abstract

We have previously reported on phase I/II studies of irinotecan plus S-1 therapy for advanced gastric cancer. Based on the safety and efficacy data that were obtained, this phase II study was planned to assess the efficacy of irinotecan plus S-1 for patients with advanced colorectral cancer. A total of 40 patients are enrolled at 13 medical institutions. The objective of this study was to establish a useful chemotherapy regimen for an out-patient setting.

Publication types

  • Clinical Trial
  • Clinical Trial, Phase II
  • Multicenter Study

MeSH terms

  • Adenocarcinoma / drug therapy*
  • Administration, Oral
  • Adolescent
  • Adult
  • Aged
  • Ambulatory Care*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Camptothecin / administration & dosage
  • Camptothecin / analogs & derivatives*
  • Colorectal Neoplasms / drug therapy*
  • Drug Administration Schedule
  • Drug Combinations
  • Humans
  • Irinotecan
  • Middle Aged
  • Oxonic Acid / administration & dosage
  • Pyridines / administration & dosage
  • Tegafur / administration & dosage

Substances

  • Drug Combinations
  • Pyridines
  • S 1 (combination)
  • Tegafur
  • Oxonic Acid
  • Irinotecan
  • Camptothecin